These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32508166)

  • 1. Non-metastatic castration-resistant prostate cancer: current status and future directions.
    Gupta R; Sheng IY; Barata PC; Garcia JA
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):513-522. PubMed ID: 32508166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists.
    Hadfield MJ; Lyall V; Holle LM; Dennison M
    Ann Pharmacother; 2023 Nov; 57(11):1302-1311. PubMed ID: 36840339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
    Alpajaro SIR; Harris JAK; Evans CP
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
    Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of apalutamide for the treatment of prostate cancer.
    Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
    Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
    Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
    Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
    [No Abstract]   [Full Text] [Related]  

  • 12. Apalutamide for the treatment of prostate cancer.
    Rathkopf DE; Scher HI
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
    Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
    J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the treatment of non-metastatic castration resistant prostate cancer.
    Esther J; Dorff TB; Maughan BL
    Cancer Treat Res Commun; 2020; 24():100181. PubMed ID: 32673844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
    Spiegelhalder P; Bögemann M
    Aktuelle Urol; 2022 Feb; 53(1):60-63. PubMed ID: 33882583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
    Hoy SM
    Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M0CRPC overview of management options.
    Hess-Busch Y; Hadaschik B; Hess J
    World J Urol; 2021 Feb; 39(2):349-356. PubMed ID: 31691081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?].
    Vis AN; van Moorselaar RJA
    Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.